Myoclonus on Morphine in Advanced Pancreatic Cancer with Renal Impairment
A 58-year-old woman with metastatic pancreatic cancer and peritoneal carcinomatosis reports pain 8/10. She takes morphine extended-release 60 mg PO every 12 hours plus immediate-release morphine 15 mg every 4 hours as needed, and has used four breakthrough doses daily for the past week. Her creatinine has risen from 1.1 to 2.6 mg/dL (eGFR 26), and she is dehydrated. Over two days she has developed diffuse myoclonus, hyperalgesia, agitation, and worsening pain despite escalating opioids. She is alert but exhausted. Her family asks you to 'increase the morphine.' Examination shows startle myoclonus and no new focal neurologic deficit.
1. What is the likely explanation for worsening pain, myoclonus, and agitation, and how do the labs change your assessment? What alternatives are on your differential?
Read the worked answer
The temporal pattern is the clue: worsening pain despite escalating morphine, new diffuse myoclonus, hyperalgesia, and agitation after creatinine doubled. That is not simply uncontrolled nociception; it suggests opioid neurotoxicity from accumulation of morphine metabolites, especially morphine-3-glucuronide and morphine-6-glucuronide, which are renally cleared. The correct response is not to increase morphine. The differential includes hypercalcemia, brain metastases, infection, urinary retention, constipation, benzodiazepine or other drug toxicity, dehydration, and akathisia. The eGFR of 26 changes both clearance and the safety margin. I would check calcium, a basic metabolic panel, and a urine study if retention is possible; review all medications, including anticholinergics and corticosteroids; and examine for a distended bladder and fecal impaction. If the myoclonus and hyperalgesia persist after stopping morphine and correcting reversible factors, the diagnosis of opioid toxicity is supported. The family's request to increase the morphine comes from seeing pain, not from understanding the pharmacology; that is a communication opportunity, not an order.
2. How would you rotate? Give a specific plan with starting doses, monitoring, and safety net, explaining the equianalgesic reasoning and incomplete cross-tolerance.
Read the worked answer
Calculate the current oral morphine daily dose: 120 mg extended-release plus up to four 15-mg breakthrough doses (60 mg) equals up to 180 mg/day. Using the rough conversion that 60 mg oral morphine/day is approximately 25 mcg/hour transdermal fentanyl, 180 mg/day is roughly 75 mcg/hour. Because of toxicity and incomplete cross-tolerance, reduce by at least 30–50%, giving approximately 25–37 mcg/hour; in a patient this ill, I would start at 12–25 mcg/hour and titrate. Stop morphine. Fentanyl is the safest major opioid in renal impairment because it has no active renally cleared metabolites. Transdermal fentanyl is slow to titrate, so use subcutaneous or intravenous fentanyl boluses for breakthrough and rapid adjustment. If hydromorphone is used instead, lower the dose and monitor closely because its metabolites can accumulate. Methadone is an option but requires expertise and ECG monitoring. Provide breakthrough dosing at 10–15% of the total daily dose and reassess every few hours initially. The conversion is imprecise; a deliberately conservative start with rescue doses and frequent reassessment is safer than a full calculated conversion.
3. What adjuvant and non-opioid strategies would you add, and what would you tell the family about 'increasing the morphine'?
Read the worked answer
Adjuvants should target the likely mechanism. Pancreatic cancer with peritoneal carcinomatosis often produces visceral and capsular pain that responds to dexamethasone 4–8 mg daily, and a celiac plexus block can substantially reduce opioid requirements. If pain is neuropathic or refractory, consider ketamine, lidocaine infusion, or radiation. For myoclonus, clonazepam or midazolam can help; for constipation, an aggressive bowel regimen is mandatory. Nonpharmacologic care includes positioning, heat, and anxiety management. When speaking with the family, I would say: 'The morphine is now causing some of the problem-the twitching and the paradoxical worsening pain. Giving more could make it worse. We are switching to a different opioid that is safer for her kidneys and adding medicines that treat the nerve and inflammation.' I would avoid framing this as withdrawal of pain treatment. I would also clarify goals: if she is dying, comfort is the priority; if she has months, a nerve block and steroid may improve function. The family should leave understanding that the plan is still aggressive comfort care, not abandonment.